Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.3% Today

What is Quidelortho Corpoation?

QuidelOrtho (QDEL) operates in the field of rapid diagnostic testing solutions. The stock experienced a notable decrease today in line with overall market conditions.

Why is Quidelortho Corpoation going down?

QDEL stock is down 5.3% on Jan 27, 2026 20:40

• Financial concerns have arisen among investors due to QDEL's low Altman Z-Score of 0.2, negative earnings, and tight balance sheet, detracting attention from its primary diagnostics focus.
• Despite surpassing Q4 earnings projections, the company's negative net margin, mixed FY2025 guidance, and recent share buybacks by top executives have influenced the bearish market trend.
• The stock has faced a significant decline in share price, weakening margins, and a high Altman Z-Score indicating financial distress, resulting in an 11% decrease aggravated by market fluctuations.
• Investor views vary, with price valuations ranging from $38 to $84, underscoring uncertainty regarding QDEL's financial future amid its diagnostic activities and resilience in the blood-supply sector.

QDEL Price Chart

QDEL Technical Analysis

QDEL News

Is QuidelOrtho’s (QDEL) Distress-Zone Z-Score Overshadowing Its Core Diagnostics Story?

QuidelOrtho (QDEL) is facing renewed scrutiny due to a distress-zone Altman Z-Score of 0.2, negative earnings, and a tight balance sheet, creating an investment narrative focused on financial risk rather than product innovation. Despite the financial concerns, the company continues its operational initiatives in diagnostics and blood-supply resilience, with upcoming Q4 and full-year 2025 results on February 11, 2026, serving as a critical event for investors seeking signs of financial improvement. The article highlights a disparity in investor fair value estimates for QDEL, ranging from US$38 to US$84, and advises readers to consider the balance sheet strain against the company's diagnostics platform.

https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-quidelorthos-qdel-distress-zone-z-score-overshadowing-its/amp

QuidelOrtho (NASDAQ:QDEL) Shares Down 7.9% - Time to Sell?

QuidelOrtho (NASDAQ:QDEL) shares dropped 7.9% on Friday to $28.16, with light trading volume. Analysts hold a "Hold" consensus rating with a target price of $39.00, though opinions vary, including recent target adjustments from UBS and JPMorgan. Despite beating Q4 earnings estimates, the company reported a negative net margin, set mixed FY2025 guidance, and saw recent share purchases by its CEO and CFO.

https://www.marketbeat.com/instant-alerts/quidelortho-nasdaqqdel-shares-down-79-time-to-sell-2026-01-23/

QuidelOrtho (QDEL) Valuation Check After Steep Share Price Slide And Rising Financial Distress Concerns

QuidelOrtho (QDEL) has seen a significant share price slide due to concerns about profitability, declining margins, and a high Altman Z-Score indicating financial distress risk. Despite a recent short-term decline, the stock has shown a mixed performance year-to-date and a 31.06% loss over one year. The article highlights a fair value estimate of $37.67, suggesting the stock might be undervalued despite the challenges, driven by assumptions around its acquisition of LEX Diagnostics and future growth.

https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/quidelortho-qdel-valuation-check-after-steep-share-price-sli

Strengthening the blood supply: Awareness, challenges and donor impact

QuidelOrtho Corporation has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. The episode discusses the pressures on the modern blood supply, including everyday and climate-driven emergencies, and the increased demand for universal blood types. It also highlights the importance of consistent donor engagement and technological advancements like standardized immunohematology platforms in strengthening blood supply resilience.

https://finviz.com/news/283571/strengthening-the-blood-supply-awareness-challenges-and-donor-impact

QuidelOrtho (QDEL) Shares Drop Over 11% Amid Market Volatility

QuidelOrtho (QDEL) stock dropped over 11% due to broader market pressures, reflecting investor concerns. The company, which specializes in rapid diagnostic testing solutions, faces financial challenges including a negative net margin, high leverage, and a low Altman Z-Score, indicating potential bankruptcy risk. Despite an average analyst target price suggesting potential upside and high institutional ownership, the company's poor financial strength and sector-specific risks contribute to its volatile market performance.

https://www.gurufocus.com/news/8540619/quidelortho-qdel-shares-drop-over-11-amid-market-volatility

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 6.6% Today

Solana ($SOL) Crypto Forecast: Up 6.3% Today

Ethereum ($ETH) Crypto Forecast: Up 5.2% Today

Hasbro Inc. ($HAS) Stock Forecast: Up 5.0% Today

Cardano ($ADA) Crypto Forecast: Up 5.6% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 5.8% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 7.9% Today

GameStop Corp. ($GME) Stock Forecast: Up 5.1% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.4% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.1% Today

Quidelortho Corpoation Price History

21.00.2026 - QDEL Stock was down 12.4%

• The bearish movement in QDEL's stock today could be attributed to profit-taking by investors after a recent strong rally.
• Despite being flagged as undervalued and receiving positive signals from analysts and research firms, concerns about the company's overdependence on the volatile respiratory business and external reimbursement policies may have dampened investor sentiment.
• The upgrade from a "strong sell" to a "hold" rating by Zacks Research, despite beating quarterly estimates, might have also contributed to the mixed investor reactions and the bearish movement in the stock today.
• Overall, while QDEL shows potential for growth with its strong product portfolio and positive analyst sentiment, investors seem to be exercising caution due to underlying challenges and uncertainties in the healthcare diagnostics industry.

28.09.2025 - QDEL Stock was down 5.8%

• The release of Episode 52 of the Science Bytes podcast featuring a Senior Global Product Manager might not have resonated well with investors, possibly indicating a lack of significant positive developments or catalysts for the company.
• Investors may have been expecting more substantial news or updates from QuidelOrtho Corporation, leading to disappointment and a bearish sentiment in the market.
• The market might be reacting to a perceived lack of innovation or growth potential in the company's recent initiatives, causing a negative impact on QDEL's stock price.

06.00.2026 - QDEL Stock was up 6.3%

• QDEL stock demonstrated strong bullish movement recently, despite some fluctuations and differing opinions among investors.
• This market trend could be linked to investor optimism regarding the company's diagnostic strategy in a competitive environment.
• The mixed assessments by analysts on QDEL's future could be a factor contributing to the stock's volatility.
• Overall, the bullish movement in QDEL stock suggests that some investors see potential for a turnaround, viewing the company as a discounted opportunity despite current market challenges.

27.00.2026 - QDEL Stock was down 5.3%

• Financial concerns have arisen among investors due to QDEL's low Altman Z-Score of 0.2, negative earnings, and tight balance sheet, detracting attention from its primary diagnostics focus.
• Despite surpassing Q4 earnings projections, the company's negative net margin, mixed FY2025 guidance, and recent share buybacks by top executives have influenced the bearish market trend.
• The stock has faced a significant decline in share price, weakening margins, and a high Altman Z-Score indicating financial distress, resulting in an 11% decrease aggravated by market fluctuations.
• Investor views vary, with price valuations ranging from $38 to $84, underscoring uncertainty regarding QDEL's financial future amid its diagnostic activities and resilience in the blood-supply sector.

10.11.2025 - QDEL Stock was up 5.0%

• The recent insider purchases by QDEL's CEO and a director have likely fueled the uptrend, indicating a belief in the company's future prospects.
• Although JPMorgan Chase & Co. reduced its stake in QDEL, the company exceeded quarterly earnings and revenue predictions, delivering a promising outlook for FY2025.
• The varied analyst consensus on QDEL, with a rating of "Reduce," may have introduced some market uncertainty. However, a projected fair value of $37.67, considering operational enhancements and margin adjustments, could have comforted investors.
• QDEL's stock currently trades at a notable discount to analyst targets, combined with a positive company outlook, contributing to today's bullish market performance.

23.00.2026 - QDEL Stock was down 7.7%

• Shares of Company Q fell over 11% due to broader market pressures, reflecting concerns about financial challenges and sector-specific risks.
• Despite surpassing Q4 earnings estimates, Company Q reported a negative net margin and high leverage, impacting market sentiment.
• Analysts' views vary, with a price target increase to $35 indicating potential upside, but the stock remains volatile due to financial weakness and market conditions.
• The recent stock price decline emphasizes the importance of monitoring financial health and profitability for future performance.

23.00.2026 - QDEL Stock was down 6.8%

• QuidelOrtho (QDEL) stock declined by over 11% due to general market pressures, indicating investor worries about the company's financial difficulties, such as negative net margin, high leverage, and potential bankruptcy concerns.
• Despite the price target for QDEL being raised to $35 by UBS and maintaining a "Neutral" rating, with a positive outlook for the respiratory season, apprehensions regarding escalating pricing risks in the Chinese diagnostics market and regulatory modifications affecting a significant portion of the company's revenue played a role in the downward movement.
• The overall market instability, alongside uncertainties in specific sectors like the Chinese market, prompted investors to respond cautiously to QuidelOrtho's stock, despite optimistic analyst predictions and heightened price targets.

16.00.2026 - QDEL Stock was down 5.9%

• An upgrade in rating from a "strong sell" to a "hold" rating led to a temporary 3.1% rise in the stock price. However, the company's negative net margin and decline in revenue contributed to a pessimistic market sentiment.
• Investor concerns may have arisen due to the substantial decrease in stake by Cwm LLC and the decision to discontinue the Savanna platform development, possibly influencing the stock's downward movement.
• Despite strong Q3 earnings and insider transactions indicating confidence, the stock price faced downward pressure given the company's high levels of debt and the perceived risk associated with debt utilization.
• The overall outlook for QuidelOrtho (QDEL) today was affected by a combination of factors including earnings results, insider activities, strategic choices, and debt levels, resulting in a bearish sentiment.

06.10.2025 - QDEL Stock was down 21.9%

• The bearish movement in QDEL stock today could be attributed to:
• 1. Despite beating earnings and revenue estimates in Q3, the decline in respiratory revenue might have raised concerns among investors about the company's future growth prospects.
• 2. The market may have reacted negatively to the bearish overall sentiment in the healthcare sector, overshadowing the positive aspects of QDEL's strong performance.
• 3. Investors might be focusing more on the potential impact of the declining respiratory revenue rather than the overall positive earnings report, leading to a sell-off in QDEL stock.

11.11.2025 - QDEL Stock was up 5.1%

• QuidelOrtho's recent 39.1% price surge has sparked discussions about its valuation, with analysts suggesting the stock is undervalued based on various metrics.
• The insider buying activity by the company's CEO and a director has reignited investor interest, indicating confidence in the company's future prospects.
• Despite concerns about declining COVID testing demand and integration challenges, QuidelOrtho's potential return to profitability this year and its current discount to analyst targets have contributed to the bullish market movement.
• The combination of positive insider buying, potential operational improvements, and undervaluation compared to analyst targets may have been key drivers behind QuidelOrtho's strong bullish performance today.

09.00.2026 - QDEL Stock was up 5.1%

• The positive movement in QDEL's stock price today may be linked to advancements in its restructuring and cost-saving initiatives, aimed at tackling obstacles in the post-pandemic market.
• Market sentiment could be influenced by potential indicators of sustained growth and successful implementation of the company's new strategy, with investors anticipating further catalysts for the stock.
• Despite reservations expressed by financial analysts and the overall cautious market environment, QDEL's robust performance today reflects a renewed investor trust in the company's capability to overcome challenges and foster future expansion.

22.00.2026 - QDEL Stock was up 6.7%

• Despite facing financial challenges such as a negative net margin and high leverage, QuidelOrtho's stock saw a significant increase following a price target raise to $35, reflecting a positive outlook on the company's future performance.
• The market reacted positively to a strong 2025-26 respiratory season outlook, even though there are concerns about potential pricing risks in QuidelOrtho's China diagnostics business.
• Analysts maintaining a "Hold" rating on QDEL but raising the target price to $35 suggests cautious optimism, balancing recent stock performance with uncertainties in the Chinese market.
• The upcoming financial results announcement for QuidelOrtho may also be contributing to the bullish sentiment surrounding the stock, as investors anticipate insights into the company's performance and future prospects.